GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (OTCPK:AVCTF) » Definitions » 5-Year ROIIC %

AVCTF (Avacta Group) 5-Year ROIIC % : -22.66% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Avacta Group 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Avacta Group's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was -22.66%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Avacta Group's 5-Year ROIIC % or its related term are showing as below:

AVCTF's 5-Year ROIIC % is ranked worse than
50.27% of 1301 companies
in the Biotechnology industry
Industry Median: -22.17 vs AVCTF: -22.66

Avacta Group 5-Year ROIIC % Historical Data

The historical data trend for Avacta Group's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group 5-Year ROIIC % Chart

Avacta Group Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,241.69 -258.54 -860.05 -21.78 -22.66

Avacta Group Semi-Annual Data
Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -21.78 - -22.66 -

Competitive Comparison of Avacta Group's 5-Year ROIIC %

For the Biotechnology subindustry, Avacta Group's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avacta Group's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Avacta Group's 5-Year ROIIC % falls into.



Avacta Group 5-Year ROIIC % Calculation

Avacta Group's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -30.8835108 (Dec. 2023) - -11.663505 (Jul. 2018) )/( 108.059 (Dec. 2023) - 22.13 (Jul. 2018) )
=-19.2200058/85.929
=-22.37%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Avacta Group  (OTCPK:AVCTF) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Avacta Group 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Avacta Group's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Avacta Group Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group Headlines

From GuruFocus

Avacta and LG Chem Life Sciences Expand Partnership

By Business Wire Business Wire 08-18-2020

Avacta announces AffyXell $7.3 Million Series A Financing

By Business Wire Business Wire 02-01-2021

Avacta's Diagnostic Division Achieves ISO 13485 Certification

By Business Wire Business Wire 07-14-2021

Avacta Submits Clinical Trial Application for AVA6000 pro-doxorubixin

By Business Wire Business Wire 12-23-2020

LG Chem Renews License Triggering Payment to Avacta

By Business Wire Business Wire 06-30-2022

First Patient Dosed in the US in Avacta's AVA6000 Phase 1 Clinical Study

By Business Wire Business Wire 04-27-2023